Walgreens Boots Alliance, Inc. (WBA) EPS Estimated At $1.55

March 19, 2018 - By Jan Rainey

 Walgreens Boots Alliance, Inc. (WBA) EPS Estimated At $1.55

Analysts expect Walgreens Boots Alliance, Inc. (NASDAQ:WBA) to report $1.55 EPS on March, 28 before the open.They anticipate $0.19 EPS change or 13.97 % from last quarter’s $1.36 EPS. WBA’s profit would be $1.54B giving it 10.90 P/E if the $1.55 EPS is correct. After having $1.28 EPS previously, Walgreens Boots Alliance, Inc.’s analysts see 21.09 % EPS growth. The stock increased 0.28% or $0.19 during the last trading session, reaching $67.57. About 10.31 million shares traded or 86.29% up from the average. Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has risen 5.77% since March 19, 2017 and is uptrending. It has underperformed by 10.93% the S&P500.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Ratings Coverage

Among 22 analysts covering Walgreens Boots Alliance (NASDAQ:WBA), 13 have Buy rating, 1 Sell and 8 Hold. Therefore 59% are positive. Walgreens Boots Alliance had 55 analyst reports since August 24, 2015 according to SRatingsIntel. Cowen & Co upgraded the stock to “Outperform” rating in Wednesday, September 9 report. The company was maintained on Monday, November 16 by Credit Suisse. UBS maintained the stock with “Buy” rating in Wednesday, August 23 report. The firm earned “Buy” rating on Tuesday, October 24 by Mizuho. The rating was initiated by UBS with “Buy” on Thursday, October 6. The firm has “Outperform” rating given on Thursday, September 1 by Credit Suisse. Citigroup maintained Walgreens Boots Alliance, Inc. (NASDAQ:WBA) rating on Thursday, November 2. Citigroup has “Buy” rating and $81 target. The stock has “Buy” rating by Zacks on Monday, August 24. Jefferies maintained Walgreens Boots Alliance, Inc. (NASDAQ:WBA) on Tuesday, September 5 with “Buy” rating. As per Tuesday, August 30, the company rating was maintained by Deutsche Bank.

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. The company has market cap of $66.94 billion. It operates through three divisions: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. It has a 18.64 P/E ratio. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: